Physician profile
Michael J Cuttica
NPI 1932224441
$402,138.15
in general payments reported to CMS, 2019-2025
14 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $21K · 2021: $39K · 2022: $36K · 2023: $45K · 2024: $108K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $197K · Consulting Fee: $31K · Travel and Lodging: $21K · Food and Beverage: $7,469 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $197,191.00 |
| Consulting Fee | $31,495.00 |
| Travel and Lodging | $21,246.45 |
| Food and Beverage | $7,468.88 |
| Education | $124.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $182,986.43 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $156,712.77 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Bayer Healthcare Pharmaceuticals INC. | $49,795.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $12,328.30 | 2024-2025 | Winrevair |
| Boston Scientific Corporation | $156.33 | 2025 | Ekosonic |
| Glaxosmithkline, LLC. | $34.86 | 2020-2023 | Nucala |
| Genentech USA, INC. | $29.54 | 2019 | |
| Melinta Therapeutics, LLC | $26.49 | 2025 | Rezzayo |
| Olympus America INC. | $22.53 | 2023 | Itind System |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2019 | |
| Allergan, INC. | $13.88 | 2019 | |
| Pfizer INC. | $12.84 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cuttica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.